Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04887948 · ClinicalTrials.gov registry record · Phase 3

Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2

A Phase 3 study, sponsored by Pfizer.

Completed
Registry status
Phase 3
Development phase
570
Enrollment target

NCT04887948: Completed Phase 3 study, sponsored by Pfizer.

NCT04887948 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 570 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (26% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04887948, a Phase 3 study, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 3
Development phase
570 participants
Enrollment target

Study Summary

Study of the safety and immunogenicity of 20vPnC and a booster dose of BNT162b2 administered at the same visit or each vaccine given alone

Primary Outcome

Local reactions included pain at injection site, redness and swelling and were recorded by participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 centimeter (cm) and graded as mild: greater than (\>) 2.0 to 5.0 cm, moderate: \>5.0 to 10.0 cm and severe: \>10.0 cm. Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity and severe: prev

Interventions

  • OTHER Saline
  • BIOLOGICAL BNT162b2
  • BIOLOGICAL 20-valent pneumococcal conjugate vaccine (20vPnC)

Trial Details

FieldValue
Enrollment Target 570 participants
Start Date 2021-05-20
Est. Completion 2021-12-08
Phase Phase 3
Pfizer

1,845 total trials

What the finished NCT04887948 record still lists

NCT04887948 is an interventional study that assigns participants to a tested intervention. The registered 570 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (26% lower).

The record links to 0 conditions, and to 3 interventions - of which Saline is the first listed.

NCT04887948 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04887948 about?

NCT04887948 is a clinical study titled "Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2". Study of the safety and immunogenicity of 20vPnC and a booster dose of BNT162b2 administered at the same visit or each vaccine given alone

What is the current status of trial NCT04887948?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 570 participants. The study started on 2021-05-20. Estimated completion is 2021-12-08.

What interventions are being tested in trial NCT04887948?

The interventions under investigation include: Saline (OTHER), BNT162b2 (BIOLOGICAL), 20-valent pneumococcal conjugate vaccine (20vPnC) (BIOLOGICAL).

Who is sponsoring clinical trial NCT04887948?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04887948's enrollment target sits among peer trials

570 665th of 2000 higher than 1,335 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05000645 · 570 participants · NA

    Grocery Delivery and Healthy Weight Gain Among Low-income Pregnant Young Women

  • NCT06239844 · 570 participants · NA

    Navigating Together for Equitable Asthma Management for Children in Families Who Communicate in Language Other Than English

  • NCT06701903 · 570 participants · Phase 2

    Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder

  • NCT07266831 · 570 participants · Phase 2

    A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04887948, the US trial registry maintained by the National Library of Medicine. NCT04887948 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.